Shelter Pharma has officially announced the launch of D3 Cure Capsules through a press release dated December 15, 2025, marking a significant expansion of its nutraceutical portfolio. The pharmaceutical company, with six decades of experience in natural healing, is strategically positioning itself to tap into the rapidly growing international vitamin D supplementation market.

Company Heritage and Vision

Shelter Pharma has spent the last six decades championing natural healing, guided by principles of tradition, integrity, and continuous progress. Since its humble beginning in 1965, the company has grown with a deep commitment to nature, blending traditional wisdom with a modern, forward-looking approach. The company combines extensive research and development with state-of-the-art technology while remaining dedicated to the natural way of healing.

Product Launch Details

The D3 Cure Capsules represent Shelter Pharma's strategic entry into addressing vitamin D deficiency, one of the most common nutritional deficiencies globally. The primary benefit of these capsules is the prevention and treatment of vitamin D deficiency, playing a crucial role in helping the body absorb calcium and phosphorus essential for maintaining overall health.

Comprehensive Health Benefits

The D3 Cure Capsules provide several significant health benefits across multiple body systems. The product supports bone health by aiding calcium absorption, helping maintain strong and healthy bones while reducing fracture risk. It is specifically used to manage conditions like osteoporosis, osteomalacia, and rickets in children.

Strategic Market Positioning

This launch is part of Shelter Pharma's comprehensive strategy to expand its nutraceutical portfolio and strengthen its presence in the wellness and preventive healthcare segment. The company believes the launch of D3 Cure Capsules will contribute positively to its growth prospects and reinforce its commitment to providing high-quality, science-backed nutritional solutions.

The company continues to focus on building a diverse portfolio of high-quality, accessible wellness products that cater to evolving consumer needs. As it deepens its presence in the nutraceutical sector, Shelter Pharma is positioned to deliver sustained growth, strengthen brand equity, and create long-term value for customers, partners, and investors alike.

Shelter Pharma Limited has announced the conversion of 7,35,000 convertible warrants into equity shares, as approved by its Board of Directors. This move has resulted in an increase in the company's paid-up share capital and a fresh infusion of funds from promoters.

Key Details of the Warrant Conversion

Impact on Share Capital

The conversion of warrants has led to an increase in Shelter Pharma's paid-up share capital:

• Previous: Rs. 15,59,77,920 (1,55,97,792 equity shares)
• New: Rs. 16,33,27,920 (1,63,32,792 equity shares)

Promoter Participation

The warrants were converted by two promoters of the company:

1. Shakil Nisarahmed Sabugar: Converted 4,50,000 warrants
2. Mustaqim Nisarahmed Sabugar: Converted 2,85,000 warrants

Financial Implications

• The company received Rs. 31.69 per warrant as the balance payment, representing 75% of the issue price.
• The total amount raised through this conversion is Rs. 2,32,90,312.50.

Regulatory Compliance

Shelter Pharma has stated that the allotment is in accordance with SEBI (ICDR) Regulations 2018 and the Companies Act, 2013. The company will apply for listing and trading approval for the newly issued shares on the BSE Limited.

Conclusion

The conversion of these warrants into equity shares demonstrates promoter confidence in the company. Shelter Pharma will likely use the raised funds for its stated business objectives, although specific details on the use of proceeds were not provided in the disclosure.